Additional Details
-
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Xentria Investigative SiteAlbany NY. 12208View Details -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Xentria Investigative SiteJacksonville FL. 32209View Details -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Xentria Investigative SitePhiladelphia PA. 19140View Details -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Xentria Investigative SiteNew York NY. 10029View Details -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Xentria Investigative SiteChicago IL. 60611View Details -
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
Xentria Investigative SiteGreenville NC. 27858View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
UCLA Health Westwood Medical PlazaWestwood CA. 90095View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteChicago IL. 60153View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteSalt Lake City UT. 84112View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteSan Diego CA. 92093View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteHouston TX. 77204View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteChicago IL. 60611View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteNew York NY. 10027View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteRichmond VA. 23284View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteMiami FL. 33146View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteDallas TX. 75204View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteOklahoma City OK. 73104View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteChicago IL. 60612View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteCharleston SC. 29425View Details -
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
aTyr Investigative SiteLos Angeles CA. 90024View Details
